1
|
Zhao J, Cochrane CS, Najeeb J, Gooden D, Sciandra C, Fan P, Lemaitre N, Newns K, Nicholas RA, Guan Z, Thaden JT, Fowler VG, Spasojevic I, Sebbane F, Toone EJ, Duncan C, Gammans R, Zhou P. Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens. Sci Transl Med 2023; 15:eadf5668. [PMID: 37556556 PMCID: PMC10785772 DOI: 10.1126/scitranslmed.adf5668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Accepted: 07/20/2023] [Indexed: 08/11/2023]
Abstract
The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme in the biosynthesis of lipid A, the outer membrane anchor of lipopolysaccharide and lipooligosaccharide in Gram-negative bacteria. The development of LpxC-targeting antibiotics toward clinical therapeutics has been hindered by the limited antibiotic profile of reported non-hydroxamate inhibitors and unexpected cardiovascular toxicity observed in certain hydroxamate and non-hydroxamate-based inhibitors. Here, we report the preclinical characterization of a slow, tight-binding LpxC inhibitor, LPC-233, with low picomolar affinity. The compound is a rapid bactericidal antibiotic, unaffected by established resistance mechanisms to commercial antibiotics, and displays outstanding activity against a wide range of Gram-negative clinical isolates in vitro. It is orally bioavailable and efficiently eliminates infections caused by susceptible and multidrug-resistant Gram-negative bacterial pathogens in murine soft tissue, sepsis, and urinary tract infection models. It displays exceptional in vitro and in vivo safety profiles, with no detectable adverse cardiovascular toxicity in dogs at 100 milligrams per kilogram. These results establish the feasibility of developing oral LpxC-targeting antibiotics for clinical applications.
Collapse
Affiliation(s)
- Jinshi Zhao
- Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA
| | | | - Javaria Najeeb
- Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA
- Current address: Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - David Gooden
- Department of Chemistry, Duke University, Durham, NC 27708, USA
- Small Molecule Synthesis Facility, Duke University, Durham, NC 27708, USA
| | - Carly Sciandra
- Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA
| | - Ping Fan
- Pharmacokinetics/Pharmacodynamics (PK/PD) Core Laboratory, Duke Cancer Institute, Durham, NC 27710, USA
| | - Nadine Lemaitre
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité de Lille, Lille, France
| | - Kate Newns
- Departments of Pharmacology and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599
- Current address: Envision Pharma Group, Philadelphia, PA 19109, USA
| | - Robert A. Nicholas
- Departments of Pharmacology and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599
| | - Ziqiang Guan
- Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA
| | - Joshua T. Thaden
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Vance G. Fowler
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Ivan Spasojevic
- Pharmacokinetics/Pharmacodynamics (PK/PD) Core Laboratory, Duke Cancer Institute, Durham, NC 27710, USA
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Florent Sebbane
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité de Lille, Lille, France
| | - Eric J. Toone
- Department of Chemistry, Duke University, Durham, NC 27708, USA
- Current address: Breakthrough Energy Ventures, 4110 Carillon Point Kirkland, WA 98033 USA
| | | | | | - Pei Zhou
- Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA
- Department of Chemistry, Duke University, Durham, NC 27708, USA
| |
Collapse
|
2
|
Choquet E, Rodriguez-Nava V, Peltier F, Wankap-Mogo R, Bergeron E, Joseph C, Lemaitre N. Nocardia neocaledoniensis as Rare Cause of Spondylodiscitis. Emerg Infect Dis 2023; 29:444-446. [PMID: 36692867 PMCID: PMC9881783 DOI: 10.3201/eid2902.221389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Nocardia neocaledoniensis is a rare species of Nocardia bacteria, identified in 2004 in hypermagnesian ultramafic soil of New Caledonia. Culture of this opportunistic pathogen from spinal biopsy samples confirmed N. neocaledoniensis spondylodiscitis in an immunocompromised man. Isolation of this unusual species from spinal biopsy samples illustrates its underappreciated ability to cause invasive infection.
Collapse
|
3
|
Bonnet I, Haddad E, Guglielmetti L, Bémer P, Bernard L, Bourgoin A, Brault R, Catho G, Caumes E, Escaut L, Fourniols E, Fréchet-Jachym M, Gaudart A, Guillot H, Lafon-Desmurs B, Lanoix JP, Lanotte P, Lemaignen A, Lemaire B, Lemaitre N, Michau C, Morand P, Mougari F, Marigot-Outtandy D, Patrat-Delon S, Perpoint T, Piau C, Pourcher V, Zarrouk V, Zeller V, Veziris N, Jauréguiberry S, Aubry A. Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms 2022; 10:microorganisms10061215. [PMID: 35744731 PMCID: PMC9229793 DOI: 10.3390/microorganisms10061215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 06/08/2022] [Accepted: 06/09/2022] [Indexed: 02/04/2023] Open
Abstract
The optimal treatment for osteoarticular infection due to multidrug-resistant tuberculosis strains (MDR-OATB) remains unclear. This study aims to evaluate the diagnosis, management and outcome of MDR-OATB in France. We present a case series of MDR-OATB patients reviewed at the French National Reference Center for Mycobacteria between 2007 and 2018. Medical history and clinical, microbiological, treatment and outcome data were collected. Twenty-three MDR-OATB cases were reported, representing 3% of all concurrent MDR-TB cases in France. Overall, 17 were male, and the median age was 32 years. Six patients were previously treated for TB, including four with first-line drugs. The most frequently affected site was the spine (n = 16). Bone and joint surgery were required in 12 patients. Twenty-one patients (91%) successfully completed the treatment with a regimen containing a mean of four drugs (range, 2-6) for a mean duration of 20 months (range, 13-27). Overall, high rates of treatment success were achieved following WHO MDR-TB treatment guidelines and individualized patient management recommendations by the French National TB Consilium. However, the optimal combination of drugs, duration of treatment and role of surgery in the management of MDR-OATB remains to be determined.
Collapse
Affiliation(s)
- Isabelle Bonnet
- Cimi-Paris, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France; (I.B.); (L.G.); (N.V.)
- Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France
- TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France
| | - Elie Haddad
- Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France; (E.H.); (E.C.); (V.P.); (S.J.)
| | - Lorenzo Guglielmetti
- Cimi-Paris, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France; (I.B.); (L.G.); (N.V.)
- Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France
- TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France
| | - Pascale Bémer
- Department of Bacteriology, University Hospital, CHU Nantes, 44000 Nantes, France;
| | - Louis Bernard
- Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, 37000 Tours, France; (L.B.); (A.L.)
| | - Anne Bourgoin
- Service de Virologie et Mycobactériologie, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France;
| | - Rachel Brault
- Service de Rhumatologie, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France;
| | - Gaud Catho
- Service de Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, 69002 Lyon, France; (G.C.); (T.P.)
| | - Eric Caumes
- Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France; (E.H.); (E.C.); (V.P.); (S.J.)
| | - Lélia Escaut
- Service de Maladies Infectieuses et Tropicales, Hôpital Bicêtre, AP-HP, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France;
| | - Eric Fourniols
- Service de Chirurgie Orthopédique, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne-Université, 75013 Paris, France;
| | - Mathilde Fréchet-Jachym
- Sanatorium, Centre Hospitalier de Bligny, 91640 Briis-sous-Forges, France; (M.F.-J.); (B.L.); (D.M.-O.)
| | - Alice Gaudart
- Service de Bactériologie, Centre Hospitalier Universitaire de Nice, 06000 Nice, France;
| | - Hélène Guillot
- Service de Médecine Interne, Hôpital Robert Ballanger, 93600 Aulnay-sous-Bois, France;
| | - Barthélémy Lafon-Desmurs
- Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France;
| | - Jean-Philippe Lanoix
- Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire d’Amiens-Picardie, 80054 Amiens, France;
| | - Philippe Lanotte
- Service de Bactériologie, Centre Hospitalier Universitaire de Tours, 37000 Tours, France;
| | - Adrien Lemaignen
- Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, 37000 Tours, France; (L.B.); (A.L.)
| | - Bénédicte Lemaire
- Sanatorium, Centre Hospitalier de Bligny, 91640 Briis-sous-Forges, France; (M.F.-J.); (B.L.); (D.M.-O.)
| | - Nadine Lemaitre
- Service de Bactériologie, Centre Hospitalier Universitaire d’Amiens-Picardie, 59200 Tourcoing, France;
| | - Christophe Michau
- Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Saint-Nazaire, 44606 Saint-Nazaire, France;
| | - Philippe Morand
- Service de Bactériologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 75014 Paris, France;
| | - Faiza Mougari
- Service de Bactériologie, Hôpital Lariboisière, AP-HP, Nord-Université de Paris, 75018 Paris, France;
| | - Dhiba Marigot-Outtandy
- Sanatorium, Centre Hospitalier de Bligny, 91640 Briis-sous-Forges, France; (M.F.-J.); (B.L.); (D.M.-O.)
| | - Solène Patrat-Delon
- Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France;
| | - Thomas Perpoint
- Service de Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, 69002 Lyon, France; (G.C.); (T.P.)
| | - Caroline Piau
- Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France;
| | - Valérie Pourcher
- Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France; (E.H.); (E.C.); (V.P.); (S.J.)
| | - Virginie Zarrouk
- Service de Médecine Interne, Hôpital Beaujon, AP-HP, Nord-Université de Paris, 92110 Clichy, France;
| | - Valérie Zeller
- Centre de Référence des Infections Ostéo-Articulaires Complexes, Groupe Hospitalier Diaconesses Croix Saint-Simon, 75020 Paris, France;
| | - Nicolas Veziris
- Cimi-Paris, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France; (I.B.); (L.G.); (N.V.)
- Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France
- TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France
- Service de Bactériologie, Hôpitaux Saint-Antoine, Tenon, Trousseau, Rothschild, AP-HP, 75012 Paris, France
| | - Stéphane Jauréguiberry
- Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France; (E.H.); (E.C.); (V.P.); (S.J.)
- Service de Maladies Infectieuses et Tropicales, Hôpital Bicêtre, AP-HP, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France;
- Centre de Référence des Infections Ostéo-Articulaires Complexes, Hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France
| | - Alexandra Aubry
- Cimi-Paris, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France; (I.B.); (L.G.); (N.V.)
- Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France
- TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France
- Centre de Référence des Infections Ostéo-Articulaires Complexes, Hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France
- Correspondence:
| |
Collapse
|
4
|
Tinévez C, Velardo F, Ranc AG, Dubois D, Pailhoriès H, Codde C, Join-Lambert O, Gras E, Corvec S, Neuwirth C, Melenotte C, Dorel M, Lagneaux AS, Pichon M, Doat V, Fournier D, Lemaignen A, Bouard L, Patoz P, Hery-Arnaud G, Lemaitre N, Couzigou C, Guillard T, Recalt E, Bille E, Belaroussi Y, Neau D, Cazanave C, Lehours P, Puges M. Retrospective multicentric study on Campylobacter spp. bacteremia in France: the Campylobacteremia study. Clin Infect Dis 2021; 75:702-709. [PMID: 34849656 DOI: 10.1093/cid/ciab983] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Campylobacter spp. bacteremia is a severe infection. A nationwide 5-year retrospective study was conducted to characterize its clinical features and prognostic factors. METHODS Patients diagnosed with Campylobacter spp. bacteremia in 37 French hospitals participating in the surveillance network of the National Reference Center for Campylobacter and Helicobacter were included from January 1, 2015, to December 31, 2019. The goal was to analyze the effects of a delay of appropriate antibiotic therapy and other risk factors on 30-day mortality, antibiotic resistance, patient characteristics and prognosis according to the Campylobacter species. FINDINGS Among the 592 patients, Campylobacter jejuni and Campylobacter fetus were the most commonly identified species (42.9 and 42.6%, respectively). The patients were elderly (median age 68 years), and most had underlying conditions, mainly immunodepression (43.4%), hematologic malignancies (25.9%), solid neoplasms (23%) and diabetes (22.3%). C. jejuni and Campylobacter coli were associated with gastrointestinal signs, and C. fetus was associated with secondary localizations. Among the 80 patients (13.5%) with secondary localizations, 12 had endocarditis, 38 vascular, 24 osteo-articular and 9 ascitic fluid infections. The thirty-day mortality rate was 11.7%, and an appropriate antibiotic treatment was independently associated with 30-day survival (odds ratio [OR]=0.47, 95% CI [0.24-0.93], p=0.03). The median efficient therapy initiation delay was quite short (2 days, IQR [0-4]) but it had no significant impact on 30-day mortality (p=0.78). INTERPRETATION Campylobacter spp. bacteremia mainly occurred in elderly immunocompromised individuals with variable clinical presentations according to the species involved. Appropriate antimicrobial therapy was associated with improved 30-day survival.
Collapse
Affiliation(s)
- Claire Tinévez
- CHU de Bordeaux, Infectious and Tropical Diseases Department, F-33000 Bordeaux, France
| | - Fanny Velardo
- INSERM, Bordeaux Population Health Research Center, ISPED, University of Bordeaux, F-33000 Bordeaux, France
| | - Anne-Gaëlle Ranc
- CHU de Lyon Sud, Bacteriology Department, F-69310 Pierre-Bénite, France
| | - Damien Dubois
- CHU de Toulouse, Bacteriology Department, F-31059 Toulouse, France
| | | | - Cyrielle Codde
- CHU de Limoges, Infectious and Tropical Diseases Department, F-87000 Limoges, France
| | | | - Emmanuelle Gras
- Hôpital Européen Georges-Pompidou, Infectious and Tropical Diseases Department, F-75015 Paris, France
| | - Stéphane Corvec
- CHU de Nantes, Bacteriology Department, F-44093 Nantes, France
| | | | - Cléa Melenotte
- CHU de Marseille, Bacteriology Department, F-13005 Marseille, France
| | - Marie Dorel
- CHU de Rennes, Infectious Diseases and Intensive Care Department, F-35033 Rennes, France
| | | | - Maxime Pichon
- CHU de Poitiers, Infectious Agents Department, Bacteriology, F-86021 Poitiers, France
| | - Violaine Doat
- CH Pierre Oudot, Biology Department, F-38300 Bourguoin-Jallieu, France
| | - Damien Fournier
- CHU de Besançon, Bacteriology Department, F-25000 Besançon, France
| | - Adrien Lemaignen
- CHRU de Tours, Infectious and Tropical Diseases Department, F-37000 Tours, France
| | - Leslie Bouard
- CHD Vendée, Biology Department, F-85000 La Roche-Sur-Yon, France
| | - Pierre Patoz
- CH de Tourcoing, Biology Department, F-59208 Tourcoing, France
| | | | - Nadine Lemaitre
- CHU d'Amiens, Bacteriology Department, F-80000 Amiens, France
| | | | - Thomas Guillard
- CHU de Reims, Bacteriology Department, F-51092 Reims, France
| | - Elise Recalt
- CHU de Strasbourg, Bacteriology Department, F-67200 Strasbourg, France
| | - Emmanuelle Bille
- CH Necker-Enfants malades, Bacteriology Department, F-75015 Paris, France
| | - Yaniss Belaroussi
- INSERM, Bordeaux Population Health Research Center, ISPED, University of Bordeaux, F-33000 Bordeaux, France
| | - Didier Neau
- CHU de Bordeaux, Infectious and Tropical Diseases Department, F-33000 Bordeaux, France
| | - Charles Cazanave
- CHU de Bordeaux, Infectious and Tropical Diseases Department, F-33000 Bordeaux, France
| | - Philippe Lehours
- CHU de Bordeaux, National Reference Center for Campylobacter and Helicobacter, Bacteriology Department, F-33000 Bordeaux, France.,Univ. Bordeaux, INSERM, UMR1053 Bordeaux Research in Translational Oncology, BaRITOn, 33076, Bordeaux, France
| | - Mathilde Puges
- CHU de Bordeaux, Infectious and Tropical Diseases Department, F-33000 Bordeaux, France
| | | |
Collapse
|
5
|
Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derks J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi-Ardekani B, Boland A, Olaso R, Meyer V, Altmuller J, Le Calvez-Kelm F, Durand G, Voegele C, Boyault S, Moonen L, Lemaitre N, Lorimier P, Toffart AC, Soltermann A, Clement JH, Saenger J, Field JK, Brevet M, Blanc-Fournier C, Galateau-Salle F, Le Stang N, Russell PA, Wright G, Sozzi G, Pastorino U, Lacomme S, Vignaud JM, Hofman V, Hofman P, Brustugun OT, Lund-Iversen M, Thomas de Montpreville V, Muscarella LA, Graziano P, Popper H, Stojsic J, Deleuze JF, Herceg Z, Viari A, Nuernberg P, Pelosi G, Dingemans AMC, Milione M, Roz L, Brcic L, Volante M, Papotti MG, Caux C, Sandoval J, Hernandez-Vargas H, Brambilla E, Speel EJM, Girard N, Lantuejoul S, McKay JD, Foll M, Fernandez-Cuesta L. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun 2019; 10:3407. [PMID: 31431620 PMCID: PMC6702229 DOI: 10.1038/s41467-019-11276-9] [Citation(s) in RCA: 94] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Accepted: 07/02/2019] [Indexed: 02/06/2023] Open
Abstract
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously proposed molecular link between the low- and high-grade lung neuroendocrine neoplasms.
Collapse
Affiliation(s)
- N Alcala
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - N Leblay
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A A G Gabriel
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - L Mangiante
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - D Hervas
- Health Research Institute La Fe, Avenida Fernando Abril Martorell, Torre 106 A 7planta, 46026, Valencia, Spain
| | - T Giffon
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A S Sertier
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - A Ferrari
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - J Derks
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - A Ghantous
- International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of Carcinogenesis, 150 Cours Albert Thomas, 69008, Lyon, France
| | - T M Delhomme
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A Chabrier
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - C Cuenin
- International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of Carcinogenesis, 150 Cours Albert Thomas, 69008, Lyon, France
| | - B Abedi-Ardekani
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A Boland
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - R Olaso
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - V Meyer
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - J Altmuller
- Cologne Centre for Genomics (CCG) and Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Weyertal 115, 50931, Cologne, Germany
| | - F Le Calvez-Kelm
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - G Durand
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - C Voegele
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - S Boyault
- Translational Research and Innovation Department, Cancer Genomic Platform, 28 Rue Laennec, 69008, Lyon, France
| | - L Moonen
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - N Lemaitre
- Institute for Advanced Biosciences, Site Santé, Allée des Alpes, 38700, La Tronche, Grenoble, France
| | - P Lorimier
- Institute for Advanced Biosciences, Site Santé, Allée des Alpes, 38700, La Tronche, Grenoble, France
| | - A C Toffart
- Pulmonology-Physiology Unit, Grenoble Alpes University Hospital, 38700, La Tronche, France
| | - A Soltermann
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland
| | - J H Clement
- Department Hematology and Medical Oncology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany
| | - J Saenger
- Bad Berka Institute of Pathology, Robert-Koch-Allee 9, 99438, Bad Berka, Germany
| | - J K Field
- Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 6 West Derby Street, L7 8TX, Liverpool, UK
| | - M Brevet
- Pathology Institute, Hospices Civils de Lyon, University Claude Bernard Lyon 1, 59 Boulevard Pinel, 69677, BRON Cedex, France
| | - C Blanc-Fournier
- CLCC François Baclesse, 3 avenue du Général Harris, 14076, Caen Cedex 5, France
| | - F Galateau-Salle
- Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373, Lyon Cedex 8, France
| | - N Le Stang
- Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373, Lyon Cedex 8, France
| | - P A Russell
- St. Vincent's Hospital and University of Melbourne, Victoria Parade, Fitzroy, Melbourne, VIC, 3065, Australia
| | - G Wright
- St. Vincent's Hospital and University of Melbourne, Victoria Parade, Fitzroy, Melbourne, VIC, 3065, Australia
| | - G Sozzi
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - U Pastorino
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - S Lacomme
- Nancy Regional University Hospital, CHRU, CRB BB-0033-00035, INSERM U1256, 29 Avenue du Maréchal de Lattre de Tassigny, 54035, Nancy Cedex, France
| | - J M Vignaud
- Nancy Regional University Hospital, CHRU, CRB BB-0033-00035, INSERM U1256, 29 Avenue du Maréchal de Lattre de Tassigny, 54035, Nancy Cedex, France
| | - V Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice Hospital, Biobank BB-0033-00025, IRCAN Inserm U1081 CNRS 7284, University Côte d'Azur, 30 avenue de la voie Romaine, CS, 51069-06001, Nice Cedex 1, France
| | - P Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice Hospital, Biobank BB-0033-00025, IRCAN Inserm U1081 CNRS 7284, University Côte d'Azur, 30 avenue de la voie Romaine, CS, 51069-06001, Nice Cedex 1, France
| | - O T Brustugun
- Drammen Hospital, Vestre Viken Health Trust, Vestre Viken HF, Postboks 800, 3004, Drammen, Norway
- Institute of Cancer Research, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway
| | - M Lund-Iversen
- Institute of Cancer Research, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway
| | | | - L A Muscarella
- Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013, San Giovanni Rotondo FG, Italy
| | - P Graziano
- Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013, San Giovanni Rotondo FG, Italy
| | - H Popper
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010, Graz, Austria
| | - J Stojsic
- Department of Thoracopulmonary Pathology, Service of Pathology, Clinical Center of Serbia, Pasterova 2, Belgrade, 11000, Serbia
| | - J F Deleuze
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - Z Herceg
- International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of Carcinogenesis, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A Viari
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - P Nuernberg
- Cologne Centre for Genomics (CCG) and Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Weyertal 115, 50931, Cologne, Germany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann-Straße 26, 50931, Cologne, Germany
| | - G Pelosi
- Department of Oncology and Hemato-Oncology, University of Milan, and Inter-Hospital Pathology Division, IRCCS Multimedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan, Italy
| | - A M C Dingemans
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - M Milione
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - L Roz
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - L Brcic
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010, Graz, Austria
| | - M Volante
- Department of Oncology, University of Turin, Pathology Division, Via Santena 7, 10126, Torino, Italy
| | - M G Papotti
- Department of Oncology, University of Turin, Pathology Division, Via Santena 7, 10126, Torino, Italy
| | - C Caux
- Department of Immunity, Virus, and Inflammation, Cancer Research Centre of Lyon (CRCL), 28 Rue Laennec, 69008, Lyon, France
| | - J Sandoval
- Health Research Institute La Fe, Avenida Fernando Abril Martorell, Torre 106 A 7planta, 46026, Valencia, Spain
| | - H Hernandez-Vargas
- Cancer Research Centre of Lyon (CRCL), Inserm U 1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, 28 Rue Laennec, 69008, Lyon, France
| | - E Brambilla
- Institute for Advanced Biosciences, Site Santé, Allée des Alpes, 38700, La Tronche, Grenoble, France
| | - E J M Speel
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - N Girard
- Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
- European Reference Network (ERN-EURACAN), 28 rue Laennec, 69008, Lyon, France
| | - S Lantuejoul
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
- Translational Research and Innovation Department, Cancer Genomic Platform, 28 Rue Laennec, 69008, Lyon, France
- Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373, Lyon Cedex 8, France
| | - J D McKay
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - M Foll
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - L Fernandez-Cuesta
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France.
| |
Collapse
|
6
|
Lange B, Khan P, Kalmambetova G, Al-Darraji HA, Alland D, Antonenka U, Brown T, Balcells ME, Blakemore R, Denkinger CM, Dheda K, Hoffmann H, Kadyrov A, Lemaitre N, Miller MB, Nikolayevskyy V, Ntinginya EN, Ozkutuk N, Palacios JJ, Popowitch EB, Porcel JM, Teo J, Theron G, Kranzer K. Diagnostic accuracy of the Xpert ® MTB/RIF cycle threshold level to predict smear positivity: a meta-analysis. Int J Tuberc Lung Dis 2018; 21:493-502. [PMID: 28399963 DOI: 10.5588/ijtld.16.0702] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
SETTING Xpert® MTB/RIF is the most widely used molecular assay for rapid diagnosis of tuberculosis (TB). The number of polymerase chain reaction cycles after which detectable product is generated (cycle threshold value, CT) correlates with the bacillary burden.OBJECTIVE To investigate the association between Xpert CT values and smear status through a systematic review and individual-level data meta-analysis. DESIGN Studies on the association between CT values and smear status were included in a descriptive systematic review. Authors of studies including smear, culture and Xpert results were asked for individual-level data, and receiver operating characteristic curves were calculated. RESULTS Of 918 citations, 10 were included in the descriptive systematic review. Fifteen data sets from studies potentially relevant for individual-level data meta-analysis provided individual-level data (7511 samples from 4447 patients); 1212 patients had positive Xpert results for at least one respiratory sample (1859 samples overall). ROC analysis revealed an area under the curve (AUC) of 0.85 (95%CI 0.82-0.87). Cut-off CT values of 27.7 and 31.8 yielded sensitivities of 85% (95%CI 83-87) and 95% (95%CI 94-96) and specificities of 67% (95%CI 66-77) and 35% (95%CI 30-41) for smear-positive samples. CONCLUSION Xpert CT values and smear status were strongly associated. However, diagnostic accuracy at set cut-off CT values of 27.7 or 31.8 would not replace smear microscopy. How CT values compare with smear microscopy in predicting infectiousness remains to be seen.
Collapse
Affiliation(s)
- B Lange
- Centre for Chronic Immunodeficiency, Division of Infectious Diseases, Department of Internal Medicine II, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany
| | - P Khan
- London School of Hygiene & Tropical Medicine, London, UK
| | - G Kalmambetova
- National TB Reference Laboratory, National Centre of Phthisiology, Bishkek, Kyrgyzstan
| | - H A Al-Darraji
- Centre of Excellence for Research in AIDS, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, Centre for International Health, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
| | - D Alland
- Division of Infectious Disease, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - U Antonenka
- Synlab MVZ Gauting, Institute of Microbiology and Laboratory Medicine, World Health Organization Supranational Reference Laboratory of Tuberculosis, Gauting, Germany
| | - T Brown
- Lung Infection and Immunity Unit, Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - M E Balcells
- Department of Infectious Diseases, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - R Blakemore
- Centre for International Health, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
| | - C M Denkinger
- Foundation for Innovative New Diagnostics, Geneva, Switzerland
| | - K Dheda
- Lung Infection and Immunity Unit, Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - H Hoffmann
- Synlab MVZ Gauting, Institute of Microbiology and Laboratory Medicine, World Health Organization Supranational Reference Laboratory of Tuberculosis, Gauting, Germany
| | - A Kadyrov
- National TB Reference Laboratory, National Centre of Phthisiology, Bishkek, Kyrgyzstan
| | - N Lemaitre
- Laboratoire de Bactériologie-Hygiène, Centre Hospitalier Universitaire, Université de Lille-Nord de France, Unité Mixte de Recherche 8204, F-59021, Institut National de la Santé et de la Recherche Médicale U1019, Lille, France
| | - M B Miller
- Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - V Nikolayevskyy
- Synlab MVZ Gauting, Institute of Microbiology and Laboratory Medicine, World Health Organization Supranational Reference Laboratory of Tuberculosis, Gauting, Germany, Department of Medicine, Imperial College London, UK
| | - E N Ntinginya
- Mbeya Medical Research Centre, National Institute for Medical Research, Dar es Salaam, Tanzania
| | - N Ozkutuk
- Celal Bayar University Faculty of Medicine, Department of Medical Microbiology, Manisa, Turkey
| | - J J Palacios
- Regional Mycobacteria Reference Center, Hospital Universitario Central de Asturias, Oviedo
| | - E B Popowitch
- Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - J M Porcel
- Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Biomedical Research Institute of Lleida, Lleida, Spain
| | - J Teo
- Microbiology Unit, Department of Laboratory Medicine, National University Hospital, Singapore
| | - G Theron
- Microbiology Unit, Department of Laboratory Medicine, National University Hospital, Singapore
| | - K Kranzer
- Department of Science & Technology/National Research Foundation of Excellence for Biomedical Tuberculosis Research, and South African Medical Research Council Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa, National Reference Laboratory for Mycobacteria, FZ Borstel, Germany
| |
Collapse
|
7
|
Butin M, Martins-Simões P, Pichon B, Leyssene D, Bordes-Couecou S, Meugnier H, Rouard C, Lemaitre N, Schramm F, Kearns A, Spiliopoulou I, Hyyryläinen HL, Dumitrescu O, Vandenesch F, Dupieux C, Laurent F. Emergence and dissemination of a linezolid-resistant Staphylococcus capitis clone in Europe. J Antimicrob Chemother 2017; 72:1014-1020. [PMID: 27999045 DOI: 10.1093/jac/dkw516] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Accepted: 11/03/2016] [Indexed: 11/13/2022] Open
Abstract
Objectives We investigated the epidemiological, clinical, microbiological and genetic characteristics of linezolid-resistant (LZR) Staphylococcus capitis isolates from French ICUs, and compared them with LZR S. capitis isolates from other European countries. Methods All LZR isolates were subjected to antimicrobial susceptibility testing (AST) and the presence of cfr and optrA genes as well as mutations in the 23S rRNA and ribosomal proteins were investigated using specific PCR with sequencing. The genetic relationship between isolates was investigated using PFGE and WGS. Epidemiological data concerning LZR S. capitis were collected retrospectively in French microbiology laboratories. Results Twenty-one LZR isolates were studied: 9 from France, 11 from Greece and 1 from Finland. All were resistant to methicillin and aminoglycosides. In addition, this unusual AST profile was identified in S. capitis isolates from seven French hospitals, and represented up to 12% of the S. capitis isolates in one centre. A G2576T mutation in 23S rRNA was identified in all isolates; cfr and optrA genes were absent. All isolates belonged to the same clone on the basis of their PFGE profiles, whatever their geographical origin. WGS found at most 212 SNPs between core genomes of the LZR isolates. Conclusions We identified and characterized an LZR S. capitis clone disseminated in three European countries, harbouring the same multiple resistance and a G2576T mutation in the 23S rRNA. The possible unrecognized wider distribution of this clone, belonging to a species classically regarded as a low-virulence skin colonizer, is of major concern not least because of the increasing use of oxazolidinones.
Collapse
Affiliation(s)
- M Butin
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France
| | - P Martins-Simões
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - B Pichon
- National Infection Service, Public Health England, Colindale, London, UK
| | - D Leyssene
- Department of Bacteriology, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - S Bordes-Couecou
- Department of Bacteriology, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - H Meugnier
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - C Rouard
- Department of Bacteriology, Hôpital Antoine-Béclère, University Paris Sud, Clamart, France
| | - N Lemaitre
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, Lille, F-59000, France
| | - F Schramm
- Department of Bacteriology, CHRU de Strasbourg, EA7290 Early Bacterial Virulence, FMTS, Université de Strasbourg, Strasbourg, France
| | - A Kearns
- National Infection Service, Public Health England, Colindale, London, UK
| | - I Spiliopoulou
- National Staphylococcal Reference Laboratory, Department of Microbiology, School of Medicine, University of Patras, Patras, Greece
| | | | - O Dumitrescu
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - F Vandenesch
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - C Dupieux
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - F Laurent
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
8
|
Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, Caumes E, Lerat I, Rioux C, Yazdanpanah Y, Tiotiu A, Lemaitre N, Brossier F, Jarlier V, Robert J, Sougakoff W, Aubry A. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur Respir J 2017; 49:13993003.01719-2016. [PMID: 28182568 DOI: 10.1183/13993003.01719-2016] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Accepted: 10/29/2016] [Indexed: 11/05/2022]
Affiliation(s)
- Nicolas Veziris
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France .,Centre National de Référence des Mycobactéries, Laboratoire de Bactériologie-Hygiène, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, APHP, Paris, France
| | - Christine Bernard
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.,Centre National de Référence des Mycobactéries, Laboratoire de Bactériologie-Hygiène, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, APHP, Paris, France
| | - Lorenzo Guglielmetti
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.,Centre National de Référence des Mycobactéries, Laboratoire de Bactériologie-Hygiène, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, APHP, Paris, France.,Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France
| | - Damien Le Du
- Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France
| | - Dhiba Marigot-Outtandy
- Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France.,AP-HP, Hôpital Raymond Poincaré, Service de Médecine Aigue Spécialisée, Garches, France
| | - Marie Jaspard
- AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service des Maladies Infectieuses et Tropicales, Paris, France
| | - Eric Caumes
- AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service des Maladies Infectieuses et Tropicales, Paris, France
| | - Isabelle Lerat
- AP-HP, Hôpital Bichat, Services de Maladies Infectieuses et Tropicales, Paris, France
| | - Christophe Rioux
- AP-HP, Hôpital Bichat, Services de Maladies Infectieuses et Tropicales, Paris, France
| | - Yazdan Yazdanpanah
- AP-HP, Hôpital Bichat, Services de Maladies Infectieuses et Tropicales, Paris, France.,INSERM, IAME, UMR 1137, Paris, France.,Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France
| | - Angelica Tiotiu
- Dépt de pneumologie, CHU de Nancy, Vandœuvre-lès-Nancy, France
| | - Nadine Lemaitre
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR, 8204 - CIIL - Center for Infection and Immunity of Lille, Lille, France
| | - Florence Brossier
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.,Centre National de Référence des Mycobactéries, Laboratoire de Bactériologie-Hygiène, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, APHP, Paris, France
| | - Vincent Jarlier
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.,Centre National de Référence des Mycobactéries, Laboratoire de Bactériologie-Hygiène, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, APHP, Paris, France
| | - Jerome Robert
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.,Centre National de Référence des Mycobactéries, Laboratoire de Bactériologie-Hygiène, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, APHP, Paris, France
| | - Wladimir Sougakoff
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.,Centre National de Référence des Mycobactéries, Laboratoire de Bactériologie-Hygiène, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, APHP, Paris, France
| | - Alexandra Aubry
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.,Centre National de Référence des Mycobactéries, Laboratoire de Bactériologie-Hygiène, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, APHP, Paris, France
| | | | | |
Collapse
|
9
|
Henoun Loukili N, Lemaitre N, Guery B, Gaillot O, Chevalier D, Mortuaire G. Is a chlorine dioxide wiping procedure suitable for the high-level disinfection of nasendoscopes? J Infect Prev 2016; 18:78-83. [PMID: 28989509 DOI: 10.1177/1757177416679879] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Accepted: 10/18/2016] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Nasendoscopes are widely used in the outpatient ENT setting. Their reprocessing requires high-level disinfection (HLD). Recently, a wiping procedure using chlorine dioxide (ClO2) has been proposed as an alternative to HLD traditional procedures. OBJECTIVE To assess the effectiveness of the HLD wiping procedure versus soaking procedure on a contaminated nasendoscope. METHOD A nasendoscope was contaminated with four strains of bacteria and Bacillus subtilis spores. After HLD either with the wiping procedure or with the soaking procedure (PA), the reduction of the initial contamination was determined. FINDINGS The wiping procedure with ClO2 displayed more than 5 log reduction for vegetative bacteria after 30 s contact time (CT) and 4 log reduction on B. subtilis spores after 2 min CT. The soaking procedure with PA displayed similar results on planktonic bacteria after 10 min CT but the log reduction of B. subtilis remained below 4. CONCLUSION The ClO2 wiping procedure showed bactericidal and sporicidal efficacy on a contaminated nasendoscope in a shorter time compared to the PA soaking procedure. Thus, ClO2 wiping procedure might be considered as an alternative to the traditional HLD procedure for nasendoscopes.
Collapse
Affiliation(s)
| | - Nadine Lemaitre
- Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Benoit Guery
- Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Olivier Gaillot
- Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | | | | |
Collapse
|
10
|
Titecat M, Liang X, Lee CJ, Charlet A, Hocquet D, Lambert T, Pagès JM, Courcol R, Sebbane F, Toone EJ, Zhou P, Lemaitre N. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors. J Antimicrob Chemother 2016; 71:2874-82. [PMID: 27330072 DOI: 10.1093/jac/dkw210] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Accepted: 05/04/2016] [Indexed: 02/02/2023] Open
Abstract
OBJECTIVES Inhibitors of uridine diphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC, which catalyses the first, irreversible step in lipid A biosynthesis) are a promising new class of antibiotics against Gram-negative bacteria. The objectives of the present study were to: (i) compare the antibiotic activities of three LpxC inhibitors (LPC-058, LPC-011 and LPC-087) and the reference inhibitor CHIR-090 against Gram-negative bacilli (including MDR and XDR isolates); and (ii) investigate the effect of combining these inhibitors with conventional antibiotics. METHODS MICs were determined for 369 clinical isolates (234 Enterobacteriaceae and 135 non-fermentative Gram-negative bacilli). Time-kill assays with LPC-058 were performed on four MDR/XDR strains, including Escherichia coli producing CTX-M-15 ESBL and Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii producing KPC-2, VIM-1 and OXA-23 carbapenemases, respectively. RESULTS LPC-058 was the most potent antibiotic and displayed the broadest spectrum of antimicrobial activity, with MIC90 values for Enterobacteriaceae, P. aeruginosa, Burkholderia cepacia and A. baumannii of 0.12, 0.5, 1 and 1 mg/L, respectively. LPC-058 was bactericidal at 1× or 2× MIC against CTX-M-15, KPC-2 and VIM-1 carbapenemase-producing strains and bacteriostatic at ≤4× MIC against OXA-23 carbapenemase-producing A. baumannii. Combinations of LPC-058 with β-lactams, amikacin and ciprofloxacin were synergistic against these strains, albeit in a species-dependent manner. LPC-058's high efficacy was attributed to the presence of the difluoromethyl-allo-threonyl head group and a linear biphenyl-diacetylene tail group. CONCLUSIONS These in vitro data highlight the therapeutic potential of the new LpxC inhibitor LPC-058 against MDR/XDR strains and set the stage for subsequent in vivo studies.
Collapse
Affiliation(s)
- Marie Titecat
- Univ. Lille, CNRS, INSERM, CHU Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Xiaofei Liang
- Department of Chemistry, Duke University, Durham, NC 27708, USA
| | - Chul-Jin Lee
- Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA
| | - Audrey Charlet
- Univ. Lille, CNRS, INSERM, CHU Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Didier Hocquet
- UMR CNRS 6249, Chrono-environnement, Université de Bourgogne-Franche-Comté, Centre de Ressources Biologiques Ferdinand Cabanne, Hygiène Hospitalière, CHU Besançon, F-25000 Besançon, France
| | - Thierry Lambert
- EA 4043 Unité Bactéries Pathogènes et Santé (UBaPS), Univ. Paris-Sud, Unité Paris Saclay, F-92290 Châtenay-Malabry, France
| | - Jean-Marie Pagès
- UMR-MD1, Aix Marseille Université, Institut de Recherche Biomédicale des Armées, F-13000 Marseille, France
| | - René Courcol
- Univ. Lille, CNRS, INSERM, CHU Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Florent Sebbane
- Univ. Lille, CNRS, INSERM, CHU Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Eric J Toone
- Department of Chemistry, Duke University, Durham, NC 27708, USA Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA
| | - Pei Zhou
- Department of Chemistry, Duke University, Durham, NC 27708, USA Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA
| | - Nadine Lemaitre
- Univ. Lille, CNRS, INSERM, CHU Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, F-59000 Lille, France
| |
Collapse
|
11
|
Demarquette H, Nudel M, Gauthier J, Bonnet S, Delvallez G, Le Grand C, Berthon C, Yakoub-Agha I, Lemaitre N, Alfandari S. BMR-03 - Facteurs de risque de bactériémie à BLSE chez les patients colonisés à BLSE en hématologie. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30312-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
12
|
Lee CJ, Liang X, Wu Q, Najeeb J, Zhao J, Gopalaswamy R, Titecat M, Sebbane F, Lemaitre N, Toone EJ, Zhou P. Drug design from the cryptic inhibitor envelope. Nat Commun 2016; 7:10638. [PMID: 26912110 PMCID: PMC4773385 DOI: 10.1038/ncomms10638] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 01/05/2016] [Indexed: 11/09/2022] Open
Abstract
Conformational dynamics plays an important role in enzyme catalysis, allosteric regulation of protein functions and assembly of macromolecular complexes. Despite these well-established roles, such information has yet to be exploited for drug design. Here we show by nuclear magnetic resonance spectroscopy that inhibitors of LpxC--an essential enzyme of the lipid A biosynthetic pathway in Gram-negative bacteria and a validated novel antibiotic target--access alternative, minor population states in solution in addition to the ligand conformation observed in crystal structures. These conformations collectively delineate an inhibitor envelope that is invisible to crystallography, but is dynamically accessible by small molecules in solution. Drug design exploiting such a hidden inhibitor envelope has led to the development of potent antibiotics with inhibition constants in the single-digit picomolar range. The principle of the cryptic inhibitor envelope approach may be broadly applicable to other lead optimization campaigns to yield improved therapeutics.
Collapse
Affiliation(s)
- Chul-Jin Lee
- Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA
| | - Xiaofei Liang
- Department of Chemistry, Duke University, Durham, North Carolina 27708, USA
| | - Qinglin Wu
- Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA
| | - Javaria Najeeb
- Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA
| | - Jinshi Zhao
- Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA
| | - Ramesh Gopalaswamy
- Department of Chemistry, Duke University, Durham, North Carolina 27708, USA
| | - Marie Titecat
- Inserm, Univ. Lille, CHU Lille, Institut Pasteur de Lille, CNRS, U1019-UMR 8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Florent Sebbane
- Inserm, Univ. Lille, CHU Lille, Institut Pasteur de Lille, CNRS, U1019-UMR 8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Nadine Lemaitre
- Inserm, Univ. Lille, CHU Lille, Institut Pasteur de Lille, CNRS, U1019-UMR 8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Eric J Toone
- Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA.,Department of Chemistry, Duke University, Durham, North Carolina 27708, USA
| | - Pei Zhou
- Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA.,Department of Chemistry, Duke University, Durham, North Carolina 27708, USA
| |
Collapse
|
13
|
Caffy F, Delbosc N, Chávez P, Lévêque P, Faure-Vincent J, Travers JP, Djurado D, Pécaut J, Grévin B, Lemaitre N, Leclerc N, Demadrille R. Synthesis, optoelectronic properties and photovoltaic performances of wide band-gap copolymers based on dibenzosilole and quinoxaline units, rivals to P3HT. Polym Chem 2016. [DOI: 10.1039/c6py00370b] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Dibenzosilole and quinoxaline based copolymers were synthesized and tested in bulk-heterojunction solar cells showing power conversion efficiencies up to 5.14%.
Collapse
|
14
|
Renvoisé A, Lemaitre N, Saintenoy G, Benosman H, Geffrier C, Epelboin L, Jarlier V, Poynard T, Thabut D. Spontaneous ascitic fluid infection and bacteremia due to Yersinia pseudotuberculosis in a liver transplant patient. Int J Infect Dis 2015; 34:122-5. [PMID: 25835101 DOI: 10.1016/j.ijid.2015.03.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 03/24/2015] [Accepted: 03/26/2015] [Indexed: 11/17/2022] Open
Abstract
We report herein a case of bacteremic ascitic fluid infection in a liver transplant patient caused by a strain of Yersinia pseudotuberculosis serogroup I that lost the yersiniabactin core. The patient's outcome was favorable after a combined therapy with a third-generation cephalosporin and gentamicin.
Collapse
Affiliation(s)
- A Renvoisé
- AP-HP, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Bactériologie-Hygiène, Paris, France; INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, team E13 (Bacteriology), Paris, France; Sorbonne Universités, UPMC Univ Paris 06, CR7, Centre d'Immunologie et des Maladies Infectieuses, CIMI, team E13 (Bacteriology), Paris, France.
| | - N Lemaitre
- CHRU Lille, Laboratoire de Bactériologie-Hygiène, Lille, France; Université Lille Nord de France, Lille, France; INSERM U1019- UMR8204, F-59021 Lille, France
| | - G Saintenoy
- AP-HP, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Bactériologie-Hygiène, Paris, France
| | - H Benosman
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Hepatogastroenterology, Paris
| | - C Geffrier
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Hepatogastroenterology, Paris
| | - L Epelboin
- AP-HP, Hôpital Pitié-Salpêtrière, Infectious and Tropical Diseases Department, Paris, France; Faculté de Médecine, Université Pierre et Marie Curie, Paris, France
| | - V Jarlier
- AP-HP, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Bactériologie-Hygiène, Paris, France; INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, team E13 (Bacteriology), Paris, France; Sorbonne Universités, UPMC Univ Paris 06, CR7, Centre d'Immunologie et des Maladies Infectieuses, CIMI, team E13 (Bacteriology), Paris, France
| | - T Poynard
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Hepatogastroenterology, Paris
| | - D Thabut
- AP-HP, Hôpital Pitié-Salpêtrière, Department of Hepatogastroenterology, Paris
| |
Collapse
|
15
|
Ducourant C, Faure K, Pichenot M, Lemaitre N, Serniclay C. U-09: Prélèvement simultané des hémocultures sur ponction veineuse unique. Med Mal Infect 2014. [DOI: 10.1016/s0399-077x(14)70358-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
16
|
Vuotto F, Berthon C, Lemaitre N, Duhamel A, Balkaran S, Le Ray E, Micol JB, Faure K, Alfandari S. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study. Am J Infect Control 2013; 41:527-30. [PMID: 23219670 DOI: 10.1016/j.ajic.2012.07.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Revised: 07/15/2012] [Accepted: 07/16/2012] [Indexed: 11/16/2022]
Abstract
BACKGROUND We observed an increased rate of Pseudomonas aeruginosa bacteremia in our hematology unit in 2004-2007 without an identified environmental source. METHODS We conducted a matched case-control study to investigate factors associated with P aeruginosa bacteremia in patients with hematologic malignancies. RESULTS Forty-two episodes of P aeruginosa bacteremia were identified. At presentation, 26 patients (62%) had pneumonia and 9 patients (21%) were in shock. Twenty-five patients (60%) were aplastic. The clinical cure rate was 40%. Comparing the 42 cases with 84 matched controls identified the following independent risk factors for P aeruginosa bacteremia: hospitalization in the previous 3 months (odds ratio [OR], 12.84; 95% confidence interval [CI], 2.98-55.18), antibiotic therapy in the previous 3 months (OR, 5.34; 95% CI, 2.14-13.30), receipt of ceftriaxone in the previous 3 months (OR, 2.38; 95% CI, 1.08-5.27), receipt of aminoglycosides in the previous 3 months (OR, 6.65; 95% CI, 1.15-38.25) and receipt of fluoroquinolones in the previous 3 months (OR, 3.22; 95% CI, 1.48-7.00). CONCLUSIONS Local antibiotic therapy algorithms were modified to decrease prescriptions of ceftriaxone and combination therapy with aminoglycosides and fluoroquinolones in an effort to decrease the risk of P aeruginosa bacteremia.
Collapse
Affiliation(s)
- Fanny Vuotto
- Department of Infectious Diseases, Claude Huriez Hospital, University of Lille, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Perron M, Lemaitre N. Expérience d’activités physiques adaptées en post réhabilitation en côte d’or. Rev Mal Respir 2006. [DOI: 10.1016/s0761-8425(06)71639-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Robert J, Bismuth R, Lemaitre N, Jarlier V. Gentamicin-susceptible or gentamicin-resistant methicillin-resistant Staphylococcus aureus: a case-case study. Infect Control Hosp Epidemiol 2006; 27:879-83. [PMID: 16874652 DOI: 10.1086/506406] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2004] [Accepted: 02/21/2005] [Indexed: 11/03/2022]
Abstract
Gentamicin-susceptible methicillin-resistant Staphylococcus aureus (GS-MRSA) strains are replacing gentamicin-resistant MRSA (GR-MRSA) strains. We showed that exposure to other patients harboring GS-MRSA was the major risk factor for GS-MRSA acquisition, and that antimicrobial exposure, especially to beta-lactams, was strongly associated with acquisition of GR-MRSA but not GS-MRSA. Gentamicin use was significantly associated with GR-MRSA acquisition in univariate analysis only.
Collapse
Affiliation(s)
- Jérôme Robert
- Laboratoire de Bactériologie-Hygiène, Faculté de Médecine Pitié-Salpétriêre, Université Pierre et Marie Curie, Paris, France.
| | | | | | | |
Collapse
|
19
|
Biron E, Carré P, Chanez P, Crestani B, Cretin C, Dautzenberg B, Eichler B, Godard P, Grignet JP, Grillet Y, Housset B, Huchon G, Jouniaux V, Lemaitre N, Muir JF, Orvoen Frija E, Pairon JC, Parlange E, Piperno D, Roche N, Roussel JC, Stoebner A, Tillie Leblond I, Trébuchon F, Valdes L. [A operational plan on behalf of chronic obstructive bronchopneumopathy. 2005-2010. Knowledge, prevention and improved management of COBP]. Rev Mal Respir 2006; 23 Spec No 3:8S9-8S55. [PMID: 17075529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
|
20
|
Lemoigne F, Desplans J, Lonsdorfer E, Lonsdorfer J, Miffre C, Perruchini JM, Chabry E, Barel P, Bernady A, Ninot G, Lemaitre N, Chouaid C. [Question 5. Strategies in respiratory therapy]. Rev Mal Respir 2005; 22:7S100-7S111. [PMID: 16340827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Affiliation(s)
- F Lemoigne
- Service de pneumologie, CHU Pasteur, 30, avenue Voie-Romaine, 06002 Nice, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Wallet F, Loïez C, Renaux E, Lemaitre N, Courcol RJ. Performances of VITEK 2 colorimetric cards for identification of gram-positive and gram-negative bacteria. J Clin Microbiol 2005; 43:4402-6. [PMID: 16145083 PMCID: PMC1234120 DOI: 10.1128/jcm.43.9.4402-4406.2005] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The purpose of this study was to evaluate the new VITEK 2 identification cards that use colorimetric reading to identify gram-positive and gram-negative bacteria (GP and GN cards, respectively) in comparison to fluorimetric cards (ID-GPC and ID-GNB, respectively). A total of 580 clinical isolates and stock collection strains belonging to 116 taxa were included in the study. Of the 249 gram-positive strains tested with both the ID-GPC and GP cards, 218 (87.5%) and 235 (94.4%) strains were correctly identified (to the genus and species level), respectively. Of the 331 gram-negative strains tested with the ID-GNB and GN cards, 295 (89.1%) and 321 (97%) strains were correctly identified, respectively. Another focus of the study was to apply the percentages of correct identifications obtained in this study to the list of bacteria isolated in our laboratory (32,739 isolates) in the year 2004. We obtained 97.9% correct identifications with the colorimetric cards and 93.9% with fluorescent cards.
Collapse
Affiliation(s)
- Frédéric Wallet
- Laboratoire de Bactériologie-Hygiène, Hôpital A. Calmette, Lille, France
| | | | | | | | | |
Collapse
|
22
|
Labidi S, Dachraoui M, Mahjoubi H, Lemaitre N, Salah RB, Mtimet S. Natural radioactive nuclides in some Tunisian thermo-mineral springs. J Environ Radioact 2002; 62:87-96. [PMID: 12141610 DOI: 10.1016/s0265-931x(01)00153-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Radioactivity in some Tunisian thermo-mineral springs (11 hot mineral springs and one cold spring) has been determined for the first time in Tunisia using radiochemical separation procedures. The obtained results show that 238U activity concentrations vary between 1.5 and about 43 mBq/l. The measured activities of 234U and 226Ra range from 1.1 to about 82.2 mBq/l and 34-3,900 mBq/l. respectively. The radioactive disequilibria in these waters are in excess of concentration of 234U compared to that of 238U. The 226Ra/234U activity ratios are high and in the range of 9.0-691.0). U, Th and Ra activities are similar to those published for other non-polluted regions of the world. Radioactivity in the only cold mineral water from Aïn Oktor is very low, and thus health hazards due to the consumption of this water are not expected.
Collapse
Affiliation(s)
- S Labidi
- Centre National de Radioprotection, Tunis, Tunisia.
| | | | | | | | | | | |
Collapse
|
23
|
Lemaitre N, Callebaut I, Frenois F, Jarlier V, Sougakoff W. Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. Biochem J 2001; 353:453-8. [PMID: 11171040 PMCID: PMC1221589 DOI: 10.1042/0264-6021:3530453] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In an attempt to investigate the molecular basis of pyrazinamide hydrolysis by the PncA protein from Mycobacterium tuberculosis, we determined the pyrazinamidase activity of nine PncA mutants bearing a single amino acid substitution. Among them, three mutants (D8G, K96T and S104R) had virtually no activity (< or =0.004 unit/mg), five (F13S, T61P, P69L, Y103S and A146V) retained a low level of activity (0.06-0.25 unit/mg) and one (T167L) exhibited a wild-type activity (1.51 units/mg). The possible structural effects of these substitutions were assessed by analysing a three-dimensional model of the PncA protein constructed on the basis of the crystal structure of the N-carbamoylsarcosine amidohydrolase (CSHase) from Arthrobacter sp., an amidohydrolase which was found by hydrophobic cluster analysis to be closely related to PncA. In the PncA model, five of the mutated residues, Asp-8, Phe-13, Lys-96, Tyr-103 and Ser-104, were located within a 6 A sphere around the cysteine residue Cys-138, which could be the counterpart of the active cysteine residue Cys-177 found in the CSHase. Among the remaining mutated residues, Thr-61, Pro-69 and Ala-146 were found to be more distant from Cys-138 but were associated with structural elements contributing to the catalytic centre, whereas Thr-167 was situated in an alpha-helix located far from the putative active site. These data suggest that the decrease in pyrazinamidase activity observed in the PncA mutant proteins is well correlated with the structural modifications the mutations can cause in the environment of the putative active cysteine Cys-138.
Collapse
Affiliation(s)
- N Lemaitre
- Laboratoire de Recherche Moléculaire sur les Antibiotiques, Faculté de Médecine Pitié-Salpêtrière, Université Paris VI, 91 bvd de l'Hôpital, 75634 Paris Cedex 13, France
| | | | | | | | | |
Collapse
|
24
|
Loïez-Durocher C, Vachée A, Lemaitre N. [Drug resistance in Mycobacterium tuberculosis: diagnostic methods]. Ann Biol Clin (Paris) 2000; 58:291-7. [PMID: 10846233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The increasing frequency of multidrug-resistant strains of M. tuberculosis becomes dramatic in industrialized countries as well as in developing countries, particularly among patients infected with human immunodeficiency virus. It needs to formulate rapid strategies for diagnosing multidrug-resistant tuberculosis. For these new drug resistance, novel detection methods are developed in order to identify the resistant strains and to undertake efficacious antituberculosis therapies more rapidly. The phenotypic methods are based on the measurement of the microbial growth on nutritional supplement with antimicrobial agents; however, these proportional methods, such as the method in solid medium, the Bactec radiometric method or the MGIT method (mycobacterial growth indicator tube), are time consuming and give results in 5 to 21 days. In contrast, the genotypic tests, using knowledge of the genes involved in the resistance, reduce the time to detection of resistance from weeks to days. After amplification of the segment of the gene encoding the drug target by PCR, these methods are based on the identification of the different mutations conferring the antimicrobial resistance in M. tuberculosis. These methods are applied with success for detection of rifampicin resistance, conferring by mutations in a defined region of the rpoB gene for 99% of cases; on the contrary, results are less for other antituberculous drugs because of the insufficiency of knowledge of the molecular basis of drug resistance.
Collapse
Affiliation(s)
- C Loïez-Durocher
- Laboratoire, Centre hospitalier, 17, boulevard Lacordaire, 59056 Roubaix
| | | | | |
Collapse
|
25
|
Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 1999; 43:1761-3. [PMID: 10390238 PMCID: PMC89359 DOI: 10.1128/aac.43.7.1761] [Citation(s) in RCA: 87] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A new set of mutations, including transposition of the insertion sequence IS6110, was identified in the pncA gene from 19 pyrazinamide-resistant Mycobacterium tuberculosis strains. Alignment of the PncA protein from M. tuberculosis with homologous proteins from different bacterial species revealed three highly conserved regions in PncA which may play an important role in the processing of pyrazinamide.
Collapse
Affiliation(s)
- N Lemaitre
- Laboratoire de Recherche Moléculaire sur les Antibiotiques, Faculté de Médecine Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France
| | | | | | | |
Collapse
|
26
|
Carbonne A, Lemaitre N, Bochet M, Truffot-Pernot C, Katlama C, Grosset J, Bricaire F, Jarlier V. Mycobacterium avium complex common-source or cross-infection in AIDS patients attending the same day-care facility. Infect Control Hosp Epidemiol 1998; 19:784-6. [PMID: 9801289 DOI: 10.1086/647725] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
To delineate the epidemiology of Mycobacterium avium complex (MAC) infection in acquired immunodeficiency syndrome patients, we studied 32 case patients with disseminated MAC infection who attended the same daycare facility during a period of 13 months. Pulsed-field gel electrophoresis analysis showed very low similarity between MAC strains, suggesting that, despite close contacts between the patients, nosocomial cross-transmission or exposure to a common source of MAC did not occur.
Collapse
Affiliation(s)
- A Carbonne
- Laboratoire de Bactériologie, Hôpital Pitié-Salpêtrière, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Carbonne A, Lemaitre N, Bochet M, Truffot-Pernot C, Katlama C, Grosset J, Bricaire F, Jarlier V. Mycobacterium avium Complex Conmmnon-Source or Cross-Infection in AIDS Patients Attending the Same Day-Care Facility. Infect Control Hosp Epidemiol 1998. [DOI: 10.2307/30141426] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
28
|
Lemaitre N, Sougakoff W, Truffot C, Grosset J, Jarlier V. [Analysis of restriction fragment length polymorphism (RFLP) of Mycobacterium tuberculosis strains isolated from patients with several episodes of tuberculosis]. Pathol Biol (Paris) 1996; 44:452-5. [PMID: 8758493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Analysis of restriction fragment length polymorphism (RFLP), using a DNA probe directed against the insertion sequence IS6110, was applied to strains of Mycobacterium tuberculosis successively isolated from four patients. In order to determine the cause of recurrence in these patients, the RFLP patterns of the corresponding isolated were analyzed. The profils obtained from the strains isolated from each of the patients were identical, thus suggesting that a relapse, rather than an exogenous reinfection with a new strain, was the cause of recurrence. The RFLP patterns of successive isolated remained unchanged during periods of time ranging from 5 months to 7 years, and were not modified after development of rifampin resistance. These results demonstrate the stability of the polymorphism detected by the IS6110 probe. Therefore, RFLP analysis is a powerfull epidemiologic tool to distinguish relapse from exogenous reinfection.
Collapse
Affiliation(s)
- N Lemaitre
- Laboratoire de Bactériologie et Centre National de Référence de la Tuberculose et des infections à Mycobactéries atypiques, Groupe Hospitalier Pitié-Salpêtriére, Paris, France
| | | | | | | | | |
Collapse
|